SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Biotricity, Inc. (BTCY) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+1381.9%).
- Analyst consensus target $4.00 (+1381.9% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 46/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — BTCY
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.42
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.55
Book Value / Share$0.00
Revenue / Share$0.64
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$4.00 (+1381.9%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-1.42 |
$0.00 |
$-5.19M |
- |
| 2017 |
$-1.81 |
$0.00 |
$-7.81M |
- |
| 2018 |
$-1.72 |
$0.00 |
$-8.62M |
- |
| 2019 |
$-1.54 |
$398.2K |
$-8.59M |
-2157.7% |
| 2020 |
$-1.85 |
$1.42M |
$-11.07M |
-780.6% |
| 2021 |
$-2.48 |
$3.38M |
$-15.49M |
-457.7% |
| 2022 |
$-3.85 |
$7.65M |
$-29.13M |
-380.8% |
| 2023 |
$-2.15 |
$9.64M |
$-18.66M |
-193.6% |
| 2024 |
$-1.66 |
$12.06M |
$-14.09M |
-116.8% |
| 2025 |
$-0.55 |
$13.79M |
$-8.42M |
-61.1% |
